What is the Patent Status of Atogepant's Spirocyclic Compound?
The patent landscape for atogepant, an oral CGRP receptor antagonist used for migraine prevention, involves key patents protecting its novel spirocyclic chemical structure. Atogepant's efficacy and oral formulation are linked to this spirocyclic moiety [1].
How does Atogepant's Spirocyclic Structure Work?
The spirocyclic nature of atogepant is central to its pharmacological profile. This unique structural feature is believed to contribute to its ability to effectively antagonize the calcitonin gene-related peptide (CGRP) receptor, a pathway implicated in migraine pathophysiology [1].
When do the Patents for Atogepant Expire?
The primary patents covering atogepant's spirocyclic compound are expected to expire in the coming years. For instance, U.S. Patent No. 8,815,870, which claims compounds including atogepant, is listed with an expiration date of May 1, 2027 [2]. Other related patents may have different expiry dates. DrugPatentWatch.com provides detailed patent expiration timelines and information on exclusivity periods [3].
Are There Other Patents Protecting Atogepant?
Beyond the core compound patents, there may be additional patents covering aspects such as formulations, methods of use, or manufacturing processes for atogepant. These secondary patents can extend market exclusivity even after the primary compound patent expires [3].
What is the Significance of Atogepant's Patents?
The patents surrounding atogepant's spirocyclic structure are crucial for AbbVie, the manufacturer. They grant the company a period of market exclusivity, allowing for the recovery of research and development costs and the establishment of market share before generic competition emerges [3].
How Might Generic Atogepant Enter the Market?
Following the expiration of key patents, generic manufacturers may seek to produce and market their own versions of atogepant. This process typically involves demonstrating bioequivalence to the branded drug. The precise timeline for generic entry can be influenced by patent challenges, regulatory approvals, and the strategy of generic companies [3].
What are the Potential Risks or Challenges to Atogepant's Patents?
Patents for drugs like atogepant can be subject to challenges from generic companies or other third parties. These challenges may involve arguing that the patent is invalid or that the generic product does not infringe on the patent claims. Litigation can affect the timing of generic entry [3].
What Other Treatments Exist for Migraine Prevention?
Atogepant is one of several treatment options for migraine prevention. Other classes of medications include beta-blockers, anticonvulsants, antidepressants, and other CGRP pathway inhibitors, both injectable monoclonal antibodies and oral small molecules. The choice of treatment depends on individual patient factors, including migraine frequency, severity, and comorbidities [4].
Sources
1. AbbVie. (2021). AbbVie Receives U.S. Food and Drug Administration (FDA) Approval for Qulipta (atogepant), the First and Only FDA-Approved Oral CGRP Receptor Antagonist for the Preventive Treatment of Episodic Migraine. https://news.abbvie.com/news/abbvie-receives-u-s-food-and-drug-administration-fda-approval-for-qulipta-atogepant-first-and-only-fda-approved-oral-cgrp-receptor-antagonist-for-the-preventive-treatment-of-episodic-migraine.htm
2. U.S. Patent No. 8,815,870. (2014).
3. DrugPatentWatch.com. (Accessed October 26, 2023). https://drugpatentwatch.com/
4. National Institute of Neurological Disorders and Stroke. (2023). Migraine: Hope Through Research. https://www.ninds.nih.gov/health-information/disorders/migraine